Literature DB >> 10981101

Importance of blood pressure reduction for prevention of progression of renal disease.

S C Textor1, V J Canzanello.   

Abstract

Despite reduction of stroke and coronary mortality rates, progression of renal disease to end stage continues to occur with increasing frequency. Recent studies emphasize common pathways of elevated arterial pressures that produce increased glomerular capillary pressures and increase filtered proteins in the urinary space. Such proteinuria, along with activation of the intrarenal renin-angiotensin system, endothelin, and inflammatory cytokines, magnifies progressive renal injury and fibrosis. Malignant forms of hypertension with severe arteriolar injury and proteinuria can be treated effectively with current antihypertensive regimens with improved patient survival. Several recent studies indicate improved renal outcomes in proteinuric diseases, generally regardless of the specific antihypertensive agent. Recent trials of hypertensive subjects with minimal proteinuria demonstrate slower rates of disease progression than that seen in subjects with proteinuria above 1 gram per day. Reduction of arterial pressures, particularly when it leads to reduced proteinuria, can slow the progression of many renal diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981101     DOI: 10.1007/s11906-999-0059-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  43 in total

1.  Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.

Authors:  I Giatras; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  1997-09-01       Impact factor: 25.391

2.  Pressure natriuresis in nitric oxide-deficient hypertensive rats: effect of antihypertensive treatments.

Authors:  L A Fortepiani; E Rodrigo; M C Ortíz; V Cachofeiro; N M Atucha; L M Ruilope; V Lahera; J García-Estañ
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

Review 3.  Modern antihypertensive treatment and the progression of renal disease.

Authors:  J H Bauer
Journal:  J Hypertens Suppl       Date:  1998-10

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.

Authors:  G Ligtenberg; P J Blankestijn; P L Oey; I H Klein; L T Dijkhorst-Oei; F Boomsma; G H Wieneke; A C van Huffelen; H A Koomans
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

Review 6.  Kidney damage in 'benign' essential hypertension.

Authors:  P K Whelton; J He; T V Perneger; M J Klag
Journal:  Curr Opin Nephrol Hypertens       Date:  1997-03       Impact factor: 2.894

7.  In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.

Authors:  P Ruggenenti; A Perna; R Benini; T Bertani; C Zoccali; Q Maggiore; M Salvadori; G Remuzzi
Journal:  J Am Soc Nephrol       Date:  1999-05       Impact factor: 10.121

8.  "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis.

Authors:  R D Toto; H C Mitchell; R D Smith; H C Lee; D McIntire; W A Pettinger
Journal:  Kidney Int       Date:  1995-09       Impact factor: 10.612

Review 9.  Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease.

Authors:  W F Clark; L M Moist
Journal:  Lupus       Date:  1998       Impact factor: 2.911

10.  Renal function during antihypertensive treatment.

Authors:  S Madhavan; D Stockwell; H Cohen; M H Alderman
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.